Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer

Cancer Genetics and Cytogenetics

Volumn 149, Issue 1, 2004, Pages 38-43

  Cavalli, Luciane R ^a,b   Singh, Baljit ^a,b   Isaacs, Claudine ^a,b   Dickson, Robert B ^a,b   Haddad, Bassem R ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DINUCLEOTIDE;

ARTICLE; BREAST; BREAST CANCER; BREAST LESION; CANCER PATIENT; CANCER SUSCEPTIBILITY; CHROMOSOME 13; CHROMOSOME 17; CHROMOSOME 3P; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM; EVALUATION; FEMALE; FHIT GENE; GENE LOCUS; GENE MUTATION; GENOME ANALYSIS; GERM LINE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHESIS; ISOLATION PROCEDURE; LASER CAPTURE MICRODISSECTION; MAMMARY GLAND; MICROSATELLITE MARKER; MORPHOLOGY; ONCOGENE; PRIORITY JOURNAL; SAMPLE; TUMOR LOCALIZATION;

EID: 0842324411     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(03)00282-6     Document Type: Article

References (30)

1. Ingvarsson S. Molecular genetics of breast cancer progression. Semin Cancer Biol. 9:1999;277-288.
2. Cornelis R.S., Neuhausen S.L., Johansson O., Arason A., Kelsell D., Ponder B.A., Tonin P., Hamann U., Lindblom A., Lalle P. The Breast Cancer Linkage Consortium. High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCA1-linked families. Genes Chromosomes Cancer. 13:1995;203-210.
3. Staff S., Nupponen N.N., Borg A., Isola J.J., Tanner M.M. Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers. Genes Chromosomes Cancer. 28:2000;432-442.
4. Nathanson K.N., Wooster R., Weber B.L. Breast cancer genetics: what we know and what we need. Nat Med. 7:2001;552-556.
5. Osorio A., de la Hoya M., Rodriguez-Lopez R., Martinez-Ramirez A., Cazorla A., Granizo J.J., Esteller M., Rivas C., Caldes T., Benitez J. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer. 99:2002;305-309.
6. Xu X., Wagner K.U., Larson D., Weaver Z., Li C., Ried T., Hennighausen L., Wynshaw-Boris A., Deng C.X. Conditional mutation of BRCA1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet. 22:1999;37-43.
7. Negrini M., Monaco C., Vorechovsky I., Ohta M., Druck T., Baffa R., Huebner K., Croce C.M. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res. 56:1996;3173-3179.
8. Campiglio M., Pekarsky Y., Menard S., Tagliabue E., Pilotti S., Croce C.M. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res. 59:1999;3866-3869.
9. Gatalica Z., Lele S.M., Rampy B.A., Norris B.A. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma. Cancer. 88:2000;1378-1383.
10. Bergthorsson J.T., Eiriksdottir G., Barkardottir R.B., Egilsson V., Arason A., Ingvarsson S. Linkage analysis and allelic imbalance in human breast cancer kindreds using microsatellite markers from the short arm of chromosome 3. Hum Genet. 96:1995;437-443.
11. Ingvarsson S., Geirsdottir E.K., Johannesdottir G., Sigbjornsdottir B.I., Eiriksdottir G., Ragnarsson G., Agnarsson B.A., Gudmundsson J., Jonasson J.G., Sigurdsson A., Egilsson V., Barkardottir R.B. High incidence of loss of heterozygosity in breast tumors from carriers of the BRCA2 999del5 mutation. Cancer Res. 58:1998;4421-4425.
12. Ingvarsson S., Agnarsson B.A., Sigbjornsdottir B.I., Kononen J., Kallioniemi O.P., Barkardottir R.B., Kovatich A.J., Schwarting R., Hauck W.W., Huebner K., McCue P.A. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. Cancer Res. 59:1999;2682-2689.
13. Emmert-Buck M.R., Bonner R.F., Smith P.D., Chuaqui R.F., Zhuang Z., Goldstein S.R., Weiss R.A., Liotta L.A. Laser capture microdissection. Science. 274:1996;998-1001.
14. Kerangueven F., Noguchi T., Coulier F., Allione F., Wargniez V., Simony-Lafontaine J., Longy M., Jacquemier J., Sobol H., Eisinger F., Birnbaum D. Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res. 57:1997;5469-5474.
15. Phelan C.M., Borg A., Cuny M., Crichton D.N., Baldersson T., Andersen T.I., Caligo M.A., Lidereau R., Lindblom A., Seitz S., Kelsell D., Hamann U., Rio P., Thorlacius S., Papp J., Olah E., Ponder B., Bignon Y.J., Scherneck S., Barkardottir R., Borresen-Dale A.L., Eyfjord J., Theillet C., Thompson A.M., Devilee P., Larsson C. Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. Cancer Res. 58:1998;1004-1012.
16. Euhus D.M., Maitra A., Wistuba I.I., Alberts A., Albores-Saavedra J., Gazdar A.F. Loss of heterozygosity at 3p in benign lesions preceding invasive breast cancer. J Surg Res. 83:1999;13-18.
17. Slaughter D.P., Southwick H.W., Smejkal W. Field cancerization in oral stratified squamous epithelium. Cancer. 6:1953;963-968.
18. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
19. Deng G., Lu Y., Zlotnikov G., Thor A.D., Smith H.S. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science. 274:1996;2057-2059.
20. Tabor M.P., Brakenhoff R.H., van Houten V.M., Kummer J.A., Snel M.H., Snijders P.J., Snow G.B., Leemans C.R., Braakhuis B.J. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res. 7:2001;1523-1532.
21. Hittelman W.N. Genetic instability in epithelial tissues at risk for cancer. Ann N Y Acad Sci. 952:2001;1-12.
22. Brennan J.A., Mao L., Hruban R.H., Boyle J.O., Eby Y.J., Koch W.M., Goodman S.N., Sidransky D. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med. 332:1995;429-435.
23. O'Connell P., Pekkel V., Fuqua S., Osborne C.K., Allred D.C. Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat. 32:1994;5-12.
24. O'Connell P., Pekkel V., Fuqua S.A., Osborne C.K., Clark G.M., Allred D.C. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst. 90:1998;697-703.
25. Washington C., Dalbegue F., Abreo F., Taubenberger J.K., Lichy J.H. Loss of heterozygosity in fibrocystic change of the breast: genetic relationship between benign proliferative lesions and associated carcinomas. Am J Pathol. 157:2000;323-329.
26. Forsti A., Louhelainen J., Soderberg M., Wijkstrom H., Hemminki K. Loss of heterozygosity in tumour-adjacent normal tissue of breast and bladder cancer. Eur J Cancer. 37:2001;1372-1380.
27. Petersson C., Pandis N., Mertens F., Adeyinka A., Ingvar C., Ringberg A., Idvall I., Bondeson L., Borg A., Olsson H., Kristoffersson U., Mitelman F. Chromosome aberrations in prophylactic mastectomies from women belonging to breast cancer families. Genes Chromosomes Cancer. 16:1996;185-188.
28. Teixeira M.R., Pandis N., Gerdes A.M., Dietrich C.U., Bardi G., Andersen J.A., Graversen H.P., Mitelman F., Heim S. Cytogenetic abnormalities in an in situ ductal carcinoma and five prophylactically removed breasts from members of a family with hereditary breast cancer. Breast Cancer Res Treat. 38:1996;177-182.
29. Dietrich C.U., Pandis N., Teixeira M.R., Bardi G., Gerdes A.M., Andersen J.A., Heim S. Chromosome abnormalities in benign hyperproliferative disorders of epithelial and stromal breast tissue. Int J Cancer. 60:1995;49-53.
30. Panagopoulos I., Pandis N., Thelin S., Petersson C., Mertens F., Borg A., Kristoffersson U., Mitelman F., Aman P. The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res. 56:1996;4871-4875.